Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Diagnos Inc V.ADK

Alternate Symbol(s):  DGNOF

Diagnos Inc. is a Canadian company, which is engaged in early detection of critical health problems based on its FLAIRE artificial intelligence (AI) platform. FLAIRE allows for quick modifying and developing of applications, such as computer assisted retina analysis (CARA). CARA’s image enhancement algorithms provide sharper, clearer and easier-to-analyze retinal images. CARA is a tool for real-time screening of large volumes of patients. It provides software-based services to assist health specialists in the detection of diabetic retinopathy and other eye-related pathologies. Its geographical areas include Canada, the United States of America, Mexico, and Chile. The Company’s subsidiaries include Diagnos Internacional SA de CV and Diagnos Healthcare (India) Private Limited.


TSXV:ADK - Post by User

Bullboard Posts
Comment by whippeton Feb 04, 2017 1:14pm
202 Views
Post# 25799834

RE:profitable

RE:profitable
Yes we are profitable for Q3.  a very good turn around story.  the stock price should move higher on those results. We show we can make money with our technology.  And the efficiency of those tests is at 98%, at a low price per test.  
.
We will now focus on the future.  Our AI technology is by far ahead of every competitor we might encounter. Also, on comparables, Google has paid much more, and is putting more money to try to develop what we have.   :)    So, right now, how much is ADK worth?  A company that now generates profits,  and is only touching a muniscule part of the market, and with no real competitor around???
.
Let's also look at the board of the company, all experts in their respective fields.!!!
.
The company is working toward new contracts, which will generate much more in the coming months, and as a target of 60-70T eye exams per months for 2017.  Guess what, we are now in 2017.  How much do we expect to charge per eye exam?  And what's % will go directly to the bottom line? these questions should be answered very shortly.  
.
And let's not forget the projet of the company, which is to develop an application for Cardio, used by our valuable AI technology. 
.
With 98% efficiency and very rapid results, i cannot believe Bayer and/or Novartis, or maybe others, are not looking at us. I just hope they wont act too soon.   :)
.
Faster, cheaper, better......   makes me think of the 6 Million $$$$$  man... but with a big multiple.   :)
.
By the way,  Gary, as per your promise,  we almost did not see you post on this board anymore......  that would have been a shame.  :)

Yes i'm smiling, with the results we got.   and come monday, i believe i'll be laughing  :)

GLTA and have a great week-end.

ps would love to read your comments, bullish or bearish.  Because that's what makes a market.
Bullboard Posts